The blood-brain barrier (BBB) constitutes a microvascular network responsible for excluding
most drugs from the brain. Treatment of brain tumors is limited by the impermeability of the …

The adenosine modulation system mostly operates through inhibitory A1 (A1R) and
facilitatory A2A receptors (A2AR) in the brain. The activity‐dependent release of adenosine …

Microglia are activated in response to a number of different pathological states within the
CNS including injury, ischemia, and infection. Microglial activation results in their production …

The past decade has seen an explosion of research on roles of neuron-astrocyte
interactions in the control of brain function. We highlight recent studies performed on the …

Adenosine is involved in a range of physiological and pathological effects through
membrane-bound receptors linked to G proteins. There are four subtypes of adenosine …

Purinergic neurotransmission, involving release of ATP as an efferent neurotransmitter was
first proposed in 1972. Later, ATP was recognised as a cotransmitter in peripheral nerves …

Adenosine kinase (ADK; EC 2.7. 1.20) is an evolutionarily conserved phosphotransferase
that converts the purine ribonucleoside adenosine into 5′-adenosine-monophosphate …

Epigenetic modifications, including changes in DNA methylation, lead to altered gene
expression and thus may underlie epileptogenesis via induction of permanent changes in …

Purinergic signalling appears to play important roles in neurodegeneration, neuroprotection
and neuroregeneration. Initially there is a brief summary of the background of purinergic …

The blood–brain barrier (BBB) is comprised of specialized endothelial cells that form the
capillary microvasculature of the CNS and is essential for brain function. It also poses the …